Opendata, web and dolomites

BITCAT SIGNED

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BITCAT project word cloud

Explore the words cloud of the BITCAT project. It provides you a very rough idea of what is the project "BITCAT" about.

protein    immunotherapeutics    vitro    renowned    immunology    isoforms    soluble    antibodies    surface    polycationic    block    pto    tested    special    propagating    oncology    immunotherapy    advantage    tumour    society    interests    utilized    ex    checkpoint    evading    scientific    mechanism    prolific    systemic    reduce    technique    receptor    completely    area    proper    employment    toxicity    class    vaccines    mcmaster    cell    anti    efficacy    potentially    escape    arose    clinical    nanoparticles    expression    candidates    advantages    world    pd    cancer    modulate    inhibition    genetics    immunity    immune    genes    canadian    ctla4    demonstrated    either    advantageous    good    researcher    liposomal    suppression    models    career    therapy    practical    tissue    university    mediated    competitive    successful    german    bioavailability    antisense    rna    exon    designed    vivo    health    drugs    considerable    l1    fraunhofer    tumours    oligonucleotides    induce    skipping    charmingly    environment    polyethylenimine    antagonistic   

Project "BITCAT" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 243˙352 €
 EC max contribution 243˙352 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-05-08   to  2020-05-07

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 243˙352.00
2    MCMASTER UNIVERSITY CA (HAMILTON) partner 0.00

Map

 Project objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity. Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed. To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms. To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution. Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BITCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

GLORIOUS (2019)

Digital Poetry in Today’s Russia: Canonisation and Translation

Read More  

Kidney-Treg (2020)

Characterisation and impact of kidney-resident Tregs in kidney physiology and pathologies

Read More